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Background: Glioblastoma multiforme (GBM) is the most aggressive of the primary brain tumors, with a grim prognosis
despite intensive treatment. In the past decades, progress in research has not significantly increased overall survival rate.
Methods: The in vitro antineoplastic effect and mechanism of action of Casiopeina III-ia (Cas III-ia), a copper compound,
on rat malignant glioma C6 cells was investigated.
Results: Cas III-ia significantly inhibited cell proliferation, inducing autophagy and apoptosis, which correlated with the
formation of autophagic vacuoles, overexpression of LC3, Beclin 1, Atg 7, Bax and Bid proteins. A decrease was detected in
the mitochondrial membrane potential and in the activity of caspase 3 and 8, together with the generation of intracellular
reactive oxygen species (ROS) and increased activity of c-jun NH2-terminal kinase (JNK). The presence of 3-methyladenine
(as selective autophagy inhibitor) increased the antineoplastic effect of Cas III-ia, while Z-VAD-FMK only showed partial
protection from the antineoplastic effect induced by Cas III-ia, and ROS antioxidants (N-acetylcysteine) decreased
apoptosis, autophagy and JNK activity. Moreover, the JNK –specific inhibitor SP600125 prevented Cas III-ia-induced cell
death.
Conclusions: Our data suggest that Cas III-ia induces cell death by autophagy and apoptosis, in part due to the activation
of ROS –dependent JNK signaling. These findings support further studies of Cas III-ia as candidate for treatment of human
malignant glioma.
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Glioma is the most common primary brain tumor in
humans [1]. Glioblastoma, a highly malignant glioma shows
extensive angiogenesis, essential for tumoral growth and
invasiveness. Its prognosis is poor and has not changed
substantially in recent decades. Malignant gliomas are
usually resistant to immunotherapy, chemotherapy, radio-
therapy, and other adjuvant therapies [2]. In addition,
glioma cells are prone to develop resistance to initially
effective therapies. Cisplatin and carboplatin are used as
first-line chemotherapy; however, significant myelosup-
pression (carboplatin) and nephrotoxicity (cisplatin) have
limited their use [3]. Therefore, it is clinically relevant to* Correspondence: trejosolis@yahoo.com.mx
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reproduction in any medium, provided the oridentify novel chemotherapeutic agents against malignant
glioma, ideally; they should show less collateral effects and
better antitumoral activity.
In the search for new anticancer agents with effective
chemotherapeutic spectrum and reduced toxicity, new sub-
stances based on endogenous (essential) metals have shown
promising initial results. Recently, a group of copper-
coordinated complexes have been developed (Casiopeinas®,
Cu(N-N)(A-A)]NO3, (A-A =N-O, O-O)) with perceptible
antineoplastic effects on human ovarian carcinoma (CH1),
murine leukemia (L1210), AS-30D rat hepatoma, cervico-
uterine (HeLa) and colon (HCT40) carcinomas [4-7].
Two major routes of programmed cell death (PCD) have
been proposed. Type I, or apoptotic cell death, is a highly
controlled process involving several well-characterized mor-
phological changes, including cell volume loss, chromaticd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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duction may involve either extracellular triggering signals
(such as tumor necrosis factor) or endogenous signals (such
as a cytochrome c release) [9], followed by the activation of
caspases and endonucleases [10]. This leads to disassembly
of nuclear chromatin and degradation of oligonucleosomal
DNA. Type II, autophagy, is a dynamic process involving
the sequestration of cytoplasmatic portions and intracellular
organelles into vacuoles called autophagosomes. These vesi-
cles are fused with lysosomes to generate autophagolyso-
somes and mature lysosomes, where the sequestered
material is degraded, leading to cell death [11].
Among the effector mechanisms involved in the con-
trol and regulation of cell death pathways, including
autophagy and apoptosis, is the cellular redox status.
The redox status in the cell is determined by the balance
between the rates of production and breakdown of re-
active oxygen and/or nitrogen species (ROS/RNS), in-
cluding free radicals such as superoxide (O2
.-), hydroxyl
radical (HO.), and non-radicals capable of generating
free radicals (i.e., H2O2) [12]. In previous studies, an-
other copper compound (Cas IIgly [Cu(4,7-dimethyl-
1,10-phenanthroline)(glycine)(H2O)]NO3) was shown to
induce a dramatic drop in intracellular levels of reduced
glutathione (GSH) in human lung cancer H157 and in
A547 cells. GSH was used as a source of electrons to
catalyze the Fenton reaction leading to ROS formation and
cell death [13]. ROS are regulators of mitogen-activated
protein kinase (MAPKS), a family of serine/threonine
kinases, which mediates intracellular signal transduction in
response to different physiological stimuli and stressing
conditions [14,15].
Three major MAPKs have been identified; c-jun NH2-
terminal kinase (JNK), p38, and extracellular signal-
regulated kinase (ERK 1/2). JNK and/or p38 activation
induce apoptosis, while ERK activation favors prolifera-
tion and promotes cell survival [16,17]. An increase in
intracellular ROS, as well as the activation of MAPKs,
participate in autophagic execution [18,19].
Here we report the mechanisms of cell death induced
in C6 glioma cells by the copper compound Casiopeina
III-ia [Cu (4,4´ dimethyl-2,2 bipiridine) (acetoacetonate)]
NO3 (Cas III-ia). Exposure of C6 glioma cells to Cas III-
ia resulted in cell death, with ultrastrucrural and bio-
chemical features consistent with autophagy and apop-
tosis. Futhermore, the involvement of ROS generation
and JNK activation as major features of the autophagic
and apoptotic pathways was demonstrated.Methods
Cas III-ia synthesis
Cas III-ia was synthesized as previously described (Ruiz-
Ramírez et al. [4]) and dissolved in sterile water.Glioma cell culture
Rat glioma C6 cells (American Tissue Culture Collection,
Rockville, Maryland, USA) were maintained at 37°C in 5%
CO2 and 95% O2 under sterile conditions in Dulbecco
modified Eagle medium (Sigma Chemical Co, St. Louis,
MO USA), supplemented with 10% fetal bovine serum
plus 10 mg streptomycin, 10,000 units pencillin and 25 μg
amphotericin B per ml (Sigma Chemical Co, St. Louis,
MO USA). After 24 h of culture, the glioma cell medium
was replaced with fresh medium plus Cas III-ia (5, 10, 15
and 20 μg/ml).
The role of autophagy, apoptosis and ROS in the anti-
neoplastic effect of CasIII-ia was examined by adding
5 mM of 3-methyladenine (3-MA; Sigma Chemical Co,
St. Louis, MO USA) or 50 μM of benzycarbonyl-Val-Ala-
Asp Z-VAD (Z-VAD-FMK; BD PharMingen, San Diego,
CA USA) or 10 mM of N-acety-L- cysteine (NAC; Sigma
Chemical Co, St. Louis, MO USA) or JNK inhibitor
(SP600125; 25 μM, Calbiochem, San Diego, Ca USA) or
ERK inhibitor (PD98059; 25 μM, San Diego, Ca USA) to
the control and the Cas III-ia treated cells. As positive
control for autophagy, C6 glioma cells were treated with
250, 500 and 1000 μM temozolamide (TMZ, Shering-
Plough Research Institute, Kenilworth, NJ, USA) with or
without 5 mM 3-MA for 24 h.
Cell viability assay
Cells were plated in 96-well microtiter plates at a density
of 5x104 per well in medium. Twenty-four h later, cells
were treated with Cas III-ia; untreated cells served as
control. After treatment for 24 h, cell viability was assayed
as described previously [20], using 3[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl-tetrazolium bromide (MTT; Roche Diag-
nostics, Mannheim, Germany).
Transmission electron microscopy
Cells were harvested, pelleted and fixed in 2.5% glutaral-
dehyde/2% PFA in a cacodylate buffer. The samples were
post-fixed with 2% osmium tetroxide for 1 h, rinsed with
fresh water and dehydrated in a graded alcohol series
(50%, 75% and 95-100%). Finally, the samples were kept
overnight in 1:1 propylene oxide/PolyBed 812, embedded
in Poly Bed 812 and cured at 60°C. Ultrathin sections
(2-3 μm) were obtained with a Reichert ultracut S micro-
tome (Leica Microsystems, Wetzlar, Germany). Sections
were stained with 2% uranyl acetate and 0.3% lead cit-
rate and photographed using a Joel 1200 EX11 Trans-
mission Electron Microscopy (Leica Microsystems, Wetzlar,
Germany) with an oil immersion Plan-Apochromat × 63/1.4
NA objective lens.
Autophagy assay
Control and treated cells (5X105) were cultured on 0.7 cm2
round glass coverslips fixed in 8-multiwell plates (Daigger,
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Tracker Red (LTR; Molecular Probes, Eugene, OR USA) at
37ºC for 10 min, to detect lysosome formation [21]. Serial
confocal images were visualized using a Zeiss LSM 510
inverted laser scanning confocal microscope (Carl Zeiss,
Oberkochen, Germany). LTR excitation at 543 nm was
provided by a helium/neon laser, and fluorescence emis-
sion was measured by a 560-nm long pass barrier filter.
Immunofluorescence assay
For immunostaining, control and treated cells were cul-
tured on 0.7 cm2 round glass coverslips in 8-multiwell
plates (Daigger, Vernon Hills, IL USA). The cells were
fixed with 4% PFA/PBS for 10 min, washed three times
with fresh PBS, permeabilized with DAKO® target retrieval
solution (DakoCytomation, Carpinteria, CA USA) for 30
min at 95°C, and finally blocked with albumin at room
temperature. Afterwards, cells were preincubated with the
primary antibody (LC3; p-JNK or p-c-jun) at a final dilu-
tion of 1:100 (Santa Cruz Biotechnology, Santa Cruz, CA
USA) for 30 min at room temperature and detected with
rhodamine-conjugated or FITC-conjugated secondary anti-
body (Jackson ImmunoResearch Laboratories, West Grove,
PA USA) at 1:200 final dilution. To visualize the fluor-
escence of the primary antibody, cells were exposed to
5 μg/ml DAPI (Vector Laboratories, Inc. Burlingame,
CA USA) and registered with a Zeiss LSM 510 inverted laser
scanning confocal microscope (Carl Zeiss, Oberkochen,
Germany).
Apoptosis determination
To assess apoptosis in C6 glioma cells after exposure to
Cas III-ia we used the in situ Cell Death Detection Kit,
with fluorescein (Roche Diagnostics, Mannheim, Germany).
Apoptotic cells were visualized using a Zeiss LSM 510
inverted laser scanning confocal microscope (Carl Zeiss,
Oberkochen, Germany). Cell death induction was moni-
tored as the appearance of the Sub-G0 peak in cell cycle
analysis. Briefly, control and treated cells (1X106) were
centrifuged and fixed overnight in 70% ethanol at 4°C; cells
were washed, incubated for 1 h in the presence of 1 mg/ml
RNAase A and 20 μg/ml propidium iodide at room
temperature, and analyzed with a Becton Dickinson (San
Jose, CA) FACScan flow cytometer.
Mitochondrial transmembrane potential assay
Mitochondrial potential was determined by analyzing the
mitochondrial retention of the cationic fluorescent dye
rhodamine 123 (Rhod 123); [22]. Briefly, 1x105 cells were
treated with Cas III-ia for 24 h, washed with PBS and
incubated with 20 μg/ml of Rhod 123 at 37°C for 20
min. Rhod 123-loaded cells were washed with fresh PBS
to eliminate excess dye. Rhod 123 fluorescence was im-
mediately measured with the FACSCalibur cytometer(Becton Dickinson, San Jose, CA USA). Data were ana-
lyzed with the Cellquest 3.1f analysis software (Becton
Dickinson, San Jose, CA USA).Cytochrome c (cyt c) release assay
Control and treated glioma C6 cells were harvested and
washed once with ice-cold PBS. The cells were then
incubated with extraction buffer (10mM Hepes, 250 mM
sucrose, 10 mM KCL, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 0.05% digitonin, and 1mM phenyl-methylsulfonyl
fluoride) at 4°C for 10 min. The supernatant containing the
cytosol proteins was used for Western blot analysis of cyt c
[23].Western blot
Samples (30 μg protein) were resolved to 10-15% SDS-
PAGE and transferred to a nitrocellulose membrane. The
membrane were subsequently blocked and incubated with
the respective primary antibody at a final dilution of 1:500
(LC3, Beclin, Atg 7, Bid, Bax; cyt c, caspase 3, Caspase 8,
p-JNK, JNK, p-ERK, ERK, c- jun, p-c-jun and β-actin
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 24
h at 4°C. Immunoreactivity was visualized by probing with
a horseradish peroxidase-conjugated secondary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA USA) and
detected using the ECL kit (Santa Cruz Biotechnology,
Santa Cruz, CA USA).Measurement of ROS formation
DCFH-DA (2',7'-dichlorofluorescein diacetate) is a stable,
non-fluorescent molecule, which is hydrolized by esterases
to the non-fluorescent DCFH (2',7'-dichlorofluorescein).
DCFH is oxidized in the presence of ROS (superoxide
anion, hydrogen peroxide, and hydroxyl radicals) turning
into the highly fluorescent 2,7-DCF [24]. For analysis of
reactive oxygen species (ROS), the DCFH-DA probe was
used as previously described [24]. Briefly, lysed cells were
diluted at 1:10 with 40 mM Tris (pH 7.4) and loaded
with 5 μM DCFH-DA (molecular probes) in methanol
for 15 min at 37°C. Subsequently, fluorescence was mea-
sured both prior to and 60 min after incubation. The for-
mation of the fluorescent oxidized derivative of DCFH,
named DCF was monitored at an excitation wavelength of
525 nm (slit 5 nm). The bucket container was thermostat-
ically maintained at 37°C. Autofluorescence of the cellular
lysate was always below 6%. The fluorescent signals of
both methanol (as vehicle) and substrates were recorded
at the baseline, prior to the calculation of DCF formation,
which was quantified using a standard curve (Sigma,
Aldrich) in methanol. Analysis was done using a Perkin-
Elmer LS50-B luminescence spectrometer.
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Total SOD activity in lysed cells was assayed as previ-
ously reported [25]. In brief, a competitive inhibition
assay was performed using a xanthine-xanthine oxidase
system to reduce NBT. The final content of the mixture
reaction was: 0.122 mM EDTA, 30.6 μM NBT, 0.122
mM xanthine, 0.006% bovine serum albumin, and 49
mM sodium carbonate. Five hundred μL of lysed cells
(1:50) were added to 2.45 mL of the mixture described
above; then 50 μL of xanthine oxidase, at a final concen-
tration of 2.8 U/L, were added and incubated in a water
bath at 27°C for 15 min. The reaction was stopped with
1 mL of 0.8 mM cupric chloride and the optical density
was read at 560 nm. One hundred percent of NBT re-
duction was obtained in a tube in which the sample was
replaced by distilled water. To measure Mn-SOD activ-
ity, CuZn-SOD activity was inhibited with DDC [25].
Mn-SOD activity was assayed by incubating the sample
with 50 mM DDC at 30°C for 1 h, which was then dia-
lyzed for 3 h with 3 changes of 400 vol of 5 mM potas-
sium phosphate buffer (pH 7.8)-0.1 mM EDTA. CuZn-
SOD activity was obtained by subtracting the activity of
the DDC-treated samples from the total SOD activity.
One unit of SOD activity was defined as the amount of
protein that inhibited NBT reduction by 50%. Results
were expressed as U/mg protein.
Catalase activity
CATactivity was determined as in the method described by
Lowry [26]. In short, the supernatant (50 μL) was added to
a quartz cuvette containing 2.95 mL of 19 mmol/L H2O2
solution prepared in potassium phosphate buffer (0.1mol/L,
pH 7.4). The change in absorbance was monitored at
240 nm over a 5-min period using a spectrophotometer
(Shimadzu UV-1201, Japan). Commercially available CAT
was used as standard. CAT activity was expressed as U/g
tissue.
Statistical analysis
All in vitro studies were made in triplicate. Data from
experiments were analyzed by one –way ANOVA followed
by Tukey’s multiple comparison test. A P value of <0.05
was considered significant.
Results
Cas III-ia induced growth inhibition and changes related
to apoptotic and non-apoptotic cell death
Exposure of C6 glioma cells during 24 h to increasing
concentrations (5-20 μg/ml) of Cas III-ia resulted in a
dose-dependent decrease of cell viability (Figure 1A). To
investigate the mechanisms by which cell viability was
reduced, ultrastructural changes were determined in C6
rat glioma cells treated with Cas III-ia for 24 h and
examined by transmission electronic microscopy. Atdoses of 5 and 10 μg/ml of Cas III-ia, cells exhibited typ-
ical apoptosis-like nuclear morphology characterized by
partial condensation and margination of chromatin along
the nuclear envelope (Figure 1B); they also showed typical
characteristics of autophagy: autophagic vacuoles delimited
by a double-membrane, which contained cytoplasmic frag-
ments. At the higher concentrations of 15 and 20 μg/ml of
Cas III-ia, autophagic vacuoles contained disintegrated cel-
lular structures, heavily vacuolized cytoplasm with a few
short channels of endoplasmic reticulum, and nuclei with
more condensed chromatin. These ultrastructural findings
suggest the activation of both autophagic and apoptotic
pathways.
Cas III-ia induced death by autophagy
LC3 and Beclin 1 overexpression were evaluated in C6
glioma cells as indicative of autophagosomal activation
[27]. The expression of LC3 was determined by immuno-
fluorescence and Western blot. Analysis of control cells
with confocal microscopy revealed the presence of a few
red granules (LC3); in contrast, in Cas III-ia treated cells
these red structures were more abundant (Figure 2A).
Two forms of LC3 have been described: LC3-I and
LC3-II (11). During formation of autophagosomes, the
LC3-I cytoplasmatic form is cleaved and liquefied to
give rise to the LC3-II membranous form. To determine
which form of LC3 is affected by the presence of Cas
III-ia, Western blot analysis was used to detected LC3-I
and LC3-II levels. Results showed increased levels of
LC3, particularly of LC3-II, leading to an increased ratio
of LC3-II/LC3-I after Cas III-ia treatment (Figure 2A).
Beclin 1 and Atg 7 expression were also determined
by Western blot. All assayed doses of Cas III-ia treat-
ment increased the expression of Beclin 1 and Atg 7
(Figure 2B). These results indicate that Cas III-ia
induced autophagy promoters such as LC3-II, Beclin 1
and Atg 7.
To determine the effect of Cas III-ia on the activation of
the lysosomal pathway, C6 glioma cells were loaded with
LTR, which is a weak base that accumulates within the
acidic lysosomal and autophagosomal compartments [21].
Confocal microscopy showed that, for all doses of Cas III-ia
assayed, total LTR uptake increased as the lysosomal/
autophagosomal compartment expanded, compared with
control cells not exposed to Cas III-ia (Figure 2C). These
results suggest that Cas III-ia induced autophagy in C6 gli-
oma cells by the induction of Beclin 1 and Atg7 proteins
and formation of autophagolysosomes.
Inhibition of Cas III-ia-induced autophagy enhances
cell death in malignant glioma cells
To assess whether autophagy was induced by the Cas
III-ia, the selective autophagy inhibitor 3-methyladenine
(3-MA) was added to C6 glioma cultures. Treatment with



































Figure 1 Cas III-ia inhibits cell proliferation and induces morphologic changes in tumor cells. A) Cell viability was determined by the MTT
assay. Data represent the mean ± SD (*P ≤ 0.05, **P≤ 0.01 and ***P≤ 0.001) of three independent experiments. B) Electron micrograph untreated
glioma C6 cells and magnified photographs of 24 h Cas III-ia-treated (5(1μm), 10 (500nm), 15(200nm) and 20 (1μm) μg/ml) glioma C6 cells. N
indicates the nucleous, open white arrows point to endoplasmatic reticulum, filled thick arrow to autophagic vacuole, asterisk for margination and
condensation of chromatin and black circles show numerous vacuoles observed by electronic microscope.
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tiated the decrease in cell viability induced by Cas III-ia
treatment at all doses: from 74% to 45% at 5 μg/ml Cas
III-ia, from 66% to 33% at 10 μg/ml, from 45% to 22% at
15 μg/ml, and from 21% to 10% at 20 μg/ml (Figure 3).
These results demonstrated that cell death is enhanced
in Cas III-ia-treated C6 glioma when autophagy is
inhibited.
As positive control of autophagy, C6 glioma cells were
treated with temozolamide (TMZ - 250, 500 and 1000 μM)
with or without 3-MA (5 mM) for 24 h. TMZ inhibited
cell viability in a dose-dependent manner. However, the
presence of 3-MA significantly increased cell viability at all
doses (Additional file l: Figure S1). TMZ, an alkylating
agent, has been reported to inhibit cell viability of malignantglioma cells in a dose-dependent manner and to induce
autophagy. When autophagy is subsequently prevented with
3-MA, localization of LC3 at the autophagosomal mem-
brane is inhibited and tumor cells are rescued from cell
death [28].
Cas III-ia induced apoptosis
To investigate the effect of Cas III-ia on apoptosis, drug-
treated cells were loaded with TUNEL staining to identify
apoptotic cells. Figure 4A shows the FITC-labeled frag-
mented DNA overlapping with the nuclear marker, DAPI.
Most cells treated with Cas III-ia presented typical apop-
totic morphology at all assayed doses, but a progressively
stronger effect was obtained with rising drug concentra-
tions (10, 15 and 20 μg/ml).
Cas III-ia 0C (µg/ml)
Cas III-ia 0A (µg/ml)
Beclin 1
β-actin
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Figure 2 The Cas III-ia induces autophagic marks. A) Analysis of LC-3 (red-rodamine and blue–DAPI) by confocal microscope (left panel) and
Western blot of LC-3 (right panel). B) Beclin 1 and Atg7 expression in cell lysates of control and Cas III-ia-treated glioma C6 cells were determined
by Western blot. C) Accumulation of LysoTracker-red was analyzed in 24 h Cas III-ia-treated glioma C6 cells and controls by confocal microscope.
The figures shown are representative of at least three different experiments for each experimental condition.
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http://www.biomedcentral.com/1471-2407/12/156Mitochondria play an important role in the regula-
tion of the apoptotic pathway, inducing a release of
apoptotic mediators (cytochrome c, Smac/Diablo, Endo
G and AIF) into the cytosol. This release is mediated by























Figure 3 3-MA enhanced cell death induced by Cas III-ia in C6
glioma cells. A) Effects of 3-MA on Cas III-ia induced cytotoxicity
were determined by the MTT assay in controls and cells treated with
Cas III-ia and Cas III-ia + 5 mM 3-MA for 24 h; data represent the
mean ± SD (*P ≤ 0.05, **P≤ 0.01 and ***P≤ 0.001) of three
independent experiments.anti or proapoptotic functions [8]. For instance, the Bid
pro-apoptotic protein, in response to an apoptotic signal,
is cleaved by caspase 8 to give rise to the C- terminal
product Bidt (truncated Bid), which is myristolated and
translocated to the mitochondria [29]. It has been
proposed that Bid participates in the permeabilization of
the outer mitochondrial membrane, and in the amplifica-
tion of the pro-apoptotic signaling of Bax, either through
direct interaction with Bax/Bak or by scavenging the anti-
apoptotic Bcl-2 and Bcl-xL, which oppose Bax activity
[30,31]. The possible participation of caspase 8, Bid and
Bax in the antineoplastic effect induced by Cas III-ia on
C6 glioma cells was examined by Western blot analysis.
Figure 4B shows the activation of caspase 8, as well as
the increment in Bid protein concentration and the
cleavage of Bid to Bidt induced by Cas III-ia at all
assayed doses, as compared with controls. In addition,
Bax content significantly increased at all assayed doses of
Cas III-ia. These results indicate the participation of caspase
8, Bidt and Bax in the antineoplastic effect of Cas III-ia on
C6 glioma cells.
The fluorescent dye Rhod 123 internalizes inside ener-
gized mitochondria. To determine changes in mitochondrial
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Figure 4 Treatment with Cas III-ia induces apoptosis in tumor cells. A) Apoptosis of control and 24 h Cas III-ia-treated glioma C6 cells (5, 10,
15 and 20 μg/ml) was determined by TUNEL assay and visualized by confocal microscope (Green-fluoresein and Blue-DAPI). The figures shown are
representative of at least three different experiments for each experimental condition. Original magnification x20 for 5 and 10 μg/ml of Cas III-ia,
and x40 for 15 and 20 μg/ml of Cas III-ia. B) Expression of capase-8, Bid and Bax proteins from controls and 24 h Cas III-ia–treated C6 glioma cells
determined by Western blot. C) Mitochondrial membrane potential from controls and 24 h Cas III-ia–treated C6 glioma cells was measured by
accumulated rodamine 123 (R123) fluorescence determined by flow cytometry. Data represent the mean ± SD (*P≤ 0.05, **P≤ 0.01 and ***P≤ 0.001)
of three independent experiments. D) cytosolic cyt c and activation of caspase 3 were determined by Western blot. The figure shown is representative
of at least three different experiments for each experimental condition. E) Effect of ZVAD on Cas III-ia induced cytotoxicity in C6 glioma cells. It was
determined by MTT assay in control cells and cells treated with Cas III-ia and Cas III-ia + 50μΜ ZVAD for 24 h; data represent the mean ± SD (*P≤ 0.05,
**P≤ 0.01 and ***P≤ 0.001) of three independent experiments.
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123 was measured. The quenching signal in Rhod-loaded
cells is indicative of loss of membrane potential and, thus,
of mitochondrial function. Changes in fluorescence were
analyzed by flow cytometry. Cas III-ia treatment decreased
the mitochondrial membrane potential by 26%, 30%, 54%
and 71% at 5, 10, 15 and 20 μg/ml of Cas III-ia, respectively
(Figure 4C).
The mitochondrial damage caused by Cas III-ia probably
results in the release of cyt c into the cytosol and the acti-
vation of caspases. The presence of cyt c in the cytosol
and activation of caspase 3 was determined by Western
blot in C6 glioma cells exposed to Cas III-ia (Figure 4D);
significant release of cyt c into the cytosol was found at
10, 15 and 20 μg/ml of Cas III-ia when compared withcontrols and significant activation of caspase 3 at all
doses of Cas III-ia. Addition of 50 μM Z-VAD-FMK
(pan-caspase inhibitor) to Cas III-ia-treated cells pro-
vided modest protection from the Cas III-ia induced
antineoplastic effect. These results suggest that apop-
tosis can be considered non-apoptotic cell death or cas-
pase-independent cell death (Figure 4E) since the activity
of caspase-3 was inhibited by Z-VAD-FMK in cells treated
with Cas III-ia. This was determined by Western blot
(Additional file 2: Figure S2).
Intracellular ROS control autophagy and apoptosis
induced by cas III-ia
The molecular mechanisms underlying the ability of Cas
III-ia to simultaneously induce autophagy and apoptosis
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duction generated by Cas III-ia was examined using the
H2O2 sensitive fluorescent probe DCHF-DA. Results
showed that incubation of cells with Cas III-ia resulted
in significant increase of ROS production at all doses
(Figure 5A). Pre-incubation of cells with the ROS scaven-
ger N-acetyl-L- cysteine, significantly blocked cell death
induced by Cas III-ia at all doses (Figure 5B). This finding
indicates that ROS are involved in the cytotoxic effect
induced by Cas III-ia. Interestingly, NAC also inhibited Bax
and Beclin-1 expression induced by Cas III-ia (10 μg/ml)
(Figure 5C). These results suggest that the presence of ROS
may profoundly affect cellular response to apoptosis and
autophagy.C























































Figure 5 Increase in cellular ROS is associated with autophagy and a
in lysed cells obtained from controls and 24-h Cas III-ia-treated C6 cells as
the mean ± SD (*P≤ 0.05, **P≤ 0.01 and ***P≤ 0.001) of three independent e
in the presence of 10 mM NAC. For cell death assay, the cells were treated wi
cytometry with propidium iodide. Data representative of means ± SD (*P ≤
C) Expression of Beclin 1 and Bax proteins in lysated cells of control and tr
NAC were determined by W. blot. The figures shown are representative ofCas III-ia induces the inactivation of antioxidant enzymes
Oxidative stress occurs as a consequence of the ROS burst.
The decreasing antioxidant system could cause the accu-
mulation of H2O2 or products of its decay and of O2. In
this context, we measured the activity of two antioxidant
enzyme types, SOD and catalase, involved in maintaining
cellular redox balance, in the cellular lysates of glioma C6
cells treated with 5, 10, 15 and 20 μg/ml Cas III-ia for 24 h
as well as in controls. Enzymatic activity of Cu/Zn-SOD
decreased significantly in glioma C6 cells at all concentra-
tions of Cas III-ia: treatment with 5, 10, 15 and 20 μg/ml
Cas III-ia caused a fall in Cu/Zn enzymatic activity of 28%,
36%, 36% and 45% (34 ± 2, 31 ± 1, 31 ± 2 and 27 ± 2 U/mg
protein), respectively, while the enzymatic activity inCas III-ia









poptosis induced by Cas III-ia. A) ROS generation was determined
described in the Materials and Methods section. Each bar represents
xperiments. B) Effect of NAC on cell death of 24 h Cas III-ia-treated cells
th 2.5, 5, 10, 15 and 20 μg/ml Cas III-ia for 25 h and analyzed by flow
0.05, **P ≤ 0.01 and ***P ≤ 0.001) of three independent experiments.
eated cells with 10μg/ml Cas III-ia, 10mM NAC and Cas III-ia + 10 mM
at least three different experiments for each experimental condition.
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http://www.biomedcentral.com/1471-2407/12/156controls was 49 ± 3.4 U/mg protein (Figure 6A). Mn-
SOD showed the same course with 25%, 50%, 50% 75%
(3 ± 0.3, 2 ± 0.1, 2 ± 0.2 and 1 ± 0.3 U/mg protein) de-
crease, respectively; the enzymatic activity in controls
being 4 ± 0.2 U/mg protein (Figure 6B). The same trend
was found for catalase (CAT) activity, which decreased
by 57%, 71%, 71% and 86% a (0.003 ± 0.0001, 0.002 ±
0.0002, 0.002 ± 0.0001 and 0.001 ± 0.0004 k/mg protein)
at 5, 10, 15 and 10 μg/ml Cas III-ia, respectively, while
enzymatic activity in controls was 0.007 ± 0.0003 k/mg
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Figure 6 Treatment with Cas III-ia induces a down in the
enzymatic activation of SOD and CAT. A) Enzymatic activity of Cu,
Zn-SOD. B) Enzymatic activity of Mn-SOD. C) Enzymatic activity of
CAT. The enzymatic activities were determined in lysated cells of
control and treated cells with Cas III-ia for the techniques described
in methods section. Data representative of means ± SD (*P≤ 0.05,
**P≤ 0.01 and ***P≤ 0.001) of three independent experiments.mechanism by which Cas III-ia induces ROS formation
may be the inactivation of SOD and CAT. Cas III-ia-
induced JNK activation determining the simultaneous
induction of autophagy and apoptosis
To investigate the role of the MAPKs pathway in Cas
III-ia induced cytotoxicity, the activation of JNK, ERK
and p38 were studied by Western blot using phosphory-
lated antibodies which select the active form of these
enzymes. We showed ERK and JNK activation, in a dose-
dependent manner (Figure 7A). However, p38 was not
activated (results not shown). One of the targets of JNK
is c-jun, a member of the AP-1 transcription factor. We
determined both, total c-jun and pc-jun by Western blot.
Figure 7A shows that the contents of p-c-jun increased
in a dose-dependent manner by Cas III-ia treatment.
In addition, JNK activation was determined at 6, 12
and 24 h in cell lysate from cells treated with 10 μg/ml
of Cas III-ia and controls. (Additional file 3: Figure S3),
the figure shows activation of JNK from 6 h to 24 h of
treatment.
To determine the involvement the MAPKs, we investi-
gated the effects of pharmacological inhibitors of JNK and
ERK. Cells were pre-incubated with or without SP600125
(25μM) or PD98059 (25μM) during 1 h, followed by Cas
III-ia treatment for 24 h. The JNK specific kinase inhibitor
SP600125 hindered the cytotoxic effects induced by Cas
III-ia at all doses; while PD98059 did not inhibit the
cytotoxic effects induced by Cas III-ia (Figure 7B). These
results suggest that JNK activation may be an important
requirement by Cas III-ia-induced cell death, and that
the participation of ERK is not critical.
ROS induce JNK activation
To determine whether Cas III-ia-induced ROS led to acti-
vation of JNK in malignant glial cells, we determined the
expression of pJNK and pc-jun by immunocytochemistry
and Western blot in non-treated cells and in cells pre-
incubated for 1 h with or without N-acety-L- cysteine
(NAC), followed by treatment with 10 μg/ml Cas III-ia
for 24 h. Figure 8A and 8B show that the activation of
JNK and c-jun induced by Cas III-ia were significantly
diminished by NAC. These results suggest that ROS
production increased by Cas III-ia contributes, at least
partially, to the activation of JNK, and that ROS is up-
stream of JNK.
Discussion
Autophagy has emerged as a powerful mediator of pro-
grammed cell death, either opposing or enhancing apop-
tosis, or acting as an alternative form of programmed cell
death, different from apoptosis [14]. The present study
shows that Cas III-ia induces cell death by both autophagy
and apoptosis in rat C6 glioma cells. A microscopic ana-
lysis of cultured cells 24 h after Cas III-ia administration
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Figure 7 Activation of JNK and ERK upon the exposure of Cas III-ia. A) Total cell lysated from control cell and treated cells with Cas III-ia (5, 10, 15
and 20 μg/ml). were inmmuno-blot for detection of phospho-JNK, total JNK, phospho-ERK, total ERK, phosphor-c-jun and total c-jun. The figures
shown are representative of at least three different experiments for each experimental condition. B) Effect of SP600125 (inhibitor de JNK) and
PD98059 (inhibitor of ERK) on cell viability of 24 h Cas III-ia treated cells. The cell viability were determined by MTT assay in control cell and
treated cells with Cas III-ia (5, 10, 15 and 20 μg/ml), Cas III-ia (5, 10, 15 and 20 μg/ml) + 25μM SP600125 and Cas III-ia (5, 10, 15 and 20 μg/ml) + 25μM
PD98059. Data representative of means ± SD (*P≤ 0.05, **P≤ 0.01 and ***P≤ 0.001) of three independent experiments.
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of both apoptosis (cell shrinkage, margination and chro-
matin condensation) and autophagy (autophagic vacuoles
and autophagosomes).
Beclin 1 is the mammalian orthologue of the yeast
Vps30/Apg6 gene, required for autophagosome formation,
and is monoallelically deleted in a high percentage of
human carcinomas [28]. In MCF7 breast carcinoma cells
the expression of Beclin 1 protein decreases below detect-
able levels. Stable transfection of Beclin 1 in MCF7 cells
promotes autophagy and reduces tumorigenic capacity,
suggesting that autophagic activity is associated with the
inhibition of cell proliferation [32]. Tamoxifen, a drug used
to treat breast cancer, may function by activating autophagy,possibly by upregulating Beclin1 in a process mediated by
ceramide [33]. In this study, we observed the inhibition of
cell viability and overexpression of the Beclin 1 protein in
C6 glioma cells after Cas III-ia treatment. Our results sug-
gest that upregulation of Beclin 1 may contribute to the
antineoplastic effect of Cas III-ia.
Recent studies have shown that LC-3, a modifier protein,
is processed by a unique protein activation/conjugation
system, to form autophagosomal membranes during autop-
hagy; where LC-3 becomes associated with an autophago-
somal precursor to form a cup-shaped pre-autophagosome,
which finally closes to form autophagosomes that engulf
the cytosolic compartment, the autophagosomes fuse with
lysosomes to form autolysosomes [34]. Present results
A
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Figure 8 ROS induce JNK activation. A) Inmunocytochemistry of phospho-JNK (red- rodamine and blue–DAPI) and phospho-c-jun (Green-FITC
and blue-DAPI) in control cells, treated with 10 μg/ml Cas III-ia and 10 μg/ml Cas III-ia + 10mM N-acety-L- cysteine (NAC) for 24 h. The figures
shown are representative of at least three different experiments for each experimental condition. Original magnification, x20. B) Western blot of
phospho-JNK and phospho-c-jun in controls, cells treated with 10 μg/ml Cas III-ia and 10 μg/ml Cas III-ia + 10mM NAC for 24 h. The figures shown
are representative of at least three different experiments for each experimental condition.
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cells, by a mechanism which is not yet clearly understood.
LTR is an acidotropic fluorescent probe used to label
and track acidic organelles in living cells, including lyso-
somes, autophagosomes, late endosomes and, to a lesser
extent, early endosomes less acidic than other organelles
[21]. An increment in LTR-flouresence represents an in-
crease in autophagosomes and autolysosomes [21]. In
our study, we observed by confocal microscopy a signifi-
cant increase in the size and number of lysosomal/
autophagosomal compartments in response to all doses
of Cas III-ia, as compared with controls.
PI3K is a conserved family of lipid kinases that catalyze
the phosphorylation of position 3 on the inositol ring of
phosphoinositides [35]. They produce lipids involved in cell
proliferation, differentiation, apoptosis, autophagy, cyto-
skeletal organization, and membrane trafficking. The drug
3-MA commonly used to inhibit the autophagic pathway
[36] interferes with the activity of class III PI3K by inter-
rupting autophagy at the sequestration step [35,37]. In ourstudy, 3-MA enhanced cell death induced by Cas III-ia in
malignant glioma cells. It seems that autophagy induced
by Cas III-ia may antagonize or delay apoptosis; thus, in-
hibition of autophagy by 3-MA may increase the sensitiv-
ity of the cell to cell death signals. Similarly, it has been
shown that the inhibition of N-(4- hydroxyphenyl) reti-
namide-induced autophagy enhances cell death in ma-
lignant glioma cells [38]. Further studies have suggested
that inhibition of autophagy induced by radiation/arsenic tri-
oxide/temozolamide decreases survival of glioma cells
[28,39,40] and that autophagy antagonizes cell death [41-43].
Our results suggest that inhibition of autophagy prevents
the removal of damaged mitochondria, promoting loss
of ΔΨm and subsequent ROS generation, thereby accel-
erating cell death. When autophagy is inhibited,
enhanced cell death may be coupled to an increase in
mitochondrial depolarization and ROS generation,
thereby increasing mitochondrial damage, and leading
to the release of cell death-inducing molecules
[38,41,42] such as cyt c, SMAC/Diablo and AIF, which
Trejo-Solís et al. BMC Cancer 2012, 12:156 Page 12 of 15
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apoptotic pathways.
This work also investigated if Cas III-ia induces apop-
tosis of C6 glioma cells. Tunnel assay results showed
that Cas III-ia induced apoptosis, with most of the cells
positive at 10, 15 and 20 μg/ml, and a slight decrease in
cell viability at 5 and 10 μg/ml of Cas III-ia, determined
by mitochondrial activity and mitochondrial membrane
potential. One possible explanation of these results is that
the TUNEL assay is not specific for cell death by apop-
tosis, since it may stain both apoptotic and autophagic
cells [44]. It has been reported that autophagy induced by
4-HPR is associated to slow loss of ΔΨm, while apoptosis
is associated to rapid loss of ΔΨm [38]. Another possible
explanation of the decrease in mitochondrial activity and
mitochondrial membrane potential at 5 and 10 μg/ml of
Cas III-ia is that Cas III-ia may initiate apoptosis by an ex-
trinsic pathway and subsequently activate an intrinsic
pathway, since Cas III-ia induces the activation of caspase
8 (the initiating caspase via death receptors) and capase 3,
formation of Bidt and Bax; all of these markers initiating











Figure 9 Suggested pathway initiated by Cas III-ia leading to autopha
stress by JNK activation. JNK can phosphorylate Bcl-2 and release Beclin 1 e
c-jun; phospho-c-jun favors the production of AP-1 which, in turn, increase
Atg7, Bax and FasL. Beclin 1 and Atg 7 may induce autophagy and FasL ca
degrades Bid into Bidt inducing Bax oligomerization and the depolarization
consequent activation of caspase 3. Autophagy and apoptosis can thus indfall in mitochondrial membrane potential was detected,
and a release of cytosolic cyt-c at high concentrations.
However, abrogation of caspase activation did not
prevent cell death; suggesting that the antineoplastic effect
of Cas III-ia can be considered as non-apoptotic cell death
or caspase-independent cell death. In a previous report we
showed that another Casiopeina, the Cas IIgly [Cu(4,7-
dimethyl-1,10-phenanthroline)(glycine)(H2O)]NO3, may
induce apoptosis in CH1 cells, with no evidence of DNA
laddering and independent of caspase activation [5]. In
C6 glioma cells, Cas IIgly also induces apoptosis by a
caspase-independent mechanism, mediated by apop-
tosis induction factor (AIF) and endonuclease G [45].
Our findings suggest that Cas III-ia induces autophagy
and apoptosis, both processes being caspase-activation
independent. Similarly, TNFα, a member of the apop-
tosis-inducing family, stimulates autophagy and apop-
tosis of T-lymphoblastic leukemia cells, independent of
caspases [46].
These results show that neither selective pharmaco-
logical inhibition of apoptosis nor of autophagy prevented
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in the cell death process.
Previous studies have shown that ROS may serve as
signaling molecules that directly or indirectly activate
both autophagy and apoptosis. Overexpression of TrkA
diminishes catalase activity, leading to the accumulation
of ROS and subsequent autophagy and apoptosis [47].
Moreover, under starving conditions, ROS oxide cysteine
residues of Atg4, induce autophagy and activate the tran-
scription of autophagy-related genes, such as Beclin1
[19,48]. In our study, Cas III-ia induced ROS generation,
and reduced SOD1, SOD2 and catalase activity. Pretreat-
ment with N-acety-L- cysteine (NAC) showed a protect-
ive effect on Cas III-ia induced cell death. Moreover,
overexpression of Beclin 1 and Bax induced by Cas III-ia
were almost completely inhibited by NAC, suggesting that
Cas III-ia induces autophagy and apoptosis by the gener-
ation of ROS.
Various stimuli activate JNK, which participates in the
regulation of fundamental cellular pathways such as autop-
hagy and apoptosis [49]. JNK phosphorylates several pro-
teins of the Bcl-2 family, resulting in inhibition of the
antiapoptotic activity of Bcl-2 and Bcl-xL, and the activa-
tion of Bax [50]. Interestingly, it has been shown that the
activation of JNK results in the phosphorylation of Bcl-2
which enhances autophagy and cell survival by disrupting
the interaction between Bcl-2 and Beclin1, while prolonged
Bcl-2 phosphorylation mediated by JNK promotes apop-
tosis [51]. Futhermore, as JNK phosphorylates the c-jun
transcription factor it promotes the upregulation of autop-
hagic and apoptotic genes, such as Beclin 1 and Fas [52];
also, JNK induces the expression of Atg7, a crucial medi-
ator of autophagosome formation [48]. In agreement with
these findings, we demonstrated that Cas III-ia induces
JNK activation, phosphorylation of c-jun and expression of
Beclin 1, Atg 7 and Bax. Pharmacological inhibition of JNK
prevented the antineoplastic effect of Cas III-ia. We also
found that ROS generation mediates the activation of JNK
in the pathway of Cas III-ia –induced cell death (Figure 9).
Most antineoplasic drugs against glioma are highly toxic
and have limited efficacy, as they also affect normal cells.
Lipopholic cation drugs concentrate into mitochondria due
to their negative electric membrane potential; the higher
plasma and mitochondrial membrane potentials of tumor
cells may enhance the selective targeting by Cas III-ia of
tumor cells, particulary inside mitochondria. Such is the
case of AS-30D hepatoma mitochondria, which exhibit
higher mitochondrial membrane potential values than
those from normal hepatocytes. Indeed, AS-30D and
HCT-40 cells in culture selectively die within 48 h of ex-
posure to Cas III-ia, co-cultured normal fibroblasts survive
[7,53] the effect of Cas III-ia (5, 10, 15, and 20 μg/ml). In
these experiments, at a 5-10 μg/ml dose of Cas III-ia, cell
viability was 100%; when the dose was increased to15 μg/ml, viability was 90%, and at 20 μg/ml, it fell
to 83%, suggesting that the metabolic effect of Cas III-ia at
5-10 μg/ml doses is fairly specific against malignant cells.
Conclusions
Our observations show that Cas III-ia promotes accumula-
tion of intracellular ROS, resulting in sustained activation
of JNK, which in turn leads to autophagy and apoptosis of
C6 glioma cells.
Taken together, present data stress the potential of this
copper compound in the therapeutic induction of cell
death of susceptible tumor cells responsive to autophagic
or apoptosis stimuli mediated by ROS induction and JNK
activation.
Additional files
Additional file 1: Figure S1: 3-MA inhibits cell death induced by
TMZ. The effects of 3-MA on TMZ induced cytotoxicity in C6 glioma
cells were determined by the MTT assay in control cells and cells treated
with TMZ and TMZ + 5 mM 3-MA for 24 h; data represent the mean ± SD
(*P ≤ 0.05, **P ≤ 0.01 and ***P≤ 0.001) of three independent experiments.
Additional file 2: Figure S2: Effect of ZVAD on caspase 3 activity.
Caspase 3 activity was determined by Western blot in control cells and cells
treated with Cas III-ia and Cas III-ia + 50μΜ ZVAD for 24 h. The figures
shown are representative of at least three different experiments for each
experimental condition.
Additional file 3: Figure S3: Persistent activation of JNK upon
exposure to Cas III-ia. Total cell lysate from control cells and cells treated
with 10 μg/ml Cas III-ia for 6, 12 and 24 h were inmmunoblotted to detect
phospho-JNK and total JNK. The figures shown are representative of at least
three different experiments for each experimental condition.
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